DexCom, Inc. (NASDAQ: DXCM) is a Healthcare company (Medical - Devices) with a market capitalization of $30.4B. The Maz Rating grades it against the other companies in its sector.
DexCom, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $81.61, DexCom, Inc. trades at 31.5x trailing earnings, 6.0x sales and 12.1x book value, with an EV/EBITDA of 19.9. Over the last twelve months it generated about $5.1B of revenue and $966M of net income. It runs a gross margin of 63.4%, an operating margin of 24.0% and a net margin of 19.4%. It shows return on equity of 36.5%, return on invested capital of 24.0% and a free cash flow yield of 3.6%. On the balance sheet: a debt-to-equity ratio of 0.55 and a current ratio of 1.74. Over the past 52 weeks the share price ranged from $56.72 to $92.59, with a beta of 1.44.
DexCom, Inc. does not currently pay a dividend.
53 Wall Street analyst ratings cover the stock: 1 Strong Buy, 43 Buy, 8 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, DexCom, Inc. (DXCM) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.81% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.24% / 30% · Interest income / Revenue 1.06% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 3.81% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.57% / 33% · Receivables / Mkt Cap (36m) 3.64% / 49% · Interest income / Revenue 1.06% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 3.81% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.57% / 33.33% · Receivables / Mkt Cap (24m) 3.64% / 33.33% · Interest income / Revenue 1.06% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 19.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 31.9% / 33.33% · Receivables / Avg Assets (4Q) 19.0% / 33.33% · Interest income / Revenue 1.06% / 5% | Pass |
| FTSE | Debt / Total Assets 19.9% / 33.33% · (Cash+ST Inv) / Total Assets 29.1% / 33.33% · (Cash+Recv) / Total Assets 48.2% / 33.33% · Interest income / Revenue 1.06% / 5% | Fail |
It depends on the standard you follow. As of September 2026, DexCom, Inc. (DXCM) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. DexCom, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.06% of each dividend: DexCom, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.